Roche Pharmaceutical Development and Sales Overview

Hemlibra Global sales CHFbn CER growth +28% Regional sales CER growth US +22% 3.2 2.8 Europe +32% 2.4 2.0 Japan +20% 1.6 1.2 International +76% 0.8 0.4 0.0 YTD Sep 19 YTD Sep 20 YTD Sep 21 YTD Sep 22 YTD Sep 2022 sales of CHF 2,778m • US: Continued share gains in non-inhibitor patients • EU: Continued share gains in non-inhibitor severe patients with market shares -60% in France, UK and GER, Italy, Spain -30% • Japan: Strong uptake in non-inhibitor patients International: Accelerating momentum with strong growth from China CER-Constant Exchange Rates Roche 153

View entire presentation